The RAINBOW study: a phase 2 trial evaluating the 3-month pharmacokinetic and pharmacodynamic data and 18-month clinical and safety outcomes of nizubaglustat in GM2 gangliosidoses or Niemann–Pick type C disease
Laura López de Frutos, Daniel Almeida do Valle, Dafne D. G. Horovitz, Mariana Horn Scherer et autres